Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata : A Systematic Review and Meta-analysis. / Sedeh, Farnam Barati; Michaelsdóttir, Thorunn Elísabet; Henning, Mattias Arvid Simon; Jemec, Gregor Borut Ernst; Ibler, Kristina Sophie.
I: Acta Dermato-Venereologica, Bind 103, adv00855, 2023.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata
T2 - A Systematic Review and Meta-analysis
AU - Sedeh, Farnam Barati
AU - Michaelsdóttir, Thorunn Elísabet
AU - Henning, Mattias Arvid Simon
AU - Jemec, Gregor Borut Ernst
AU - Ibler, Kristina Sophie
N1 - Publisher Copyright: © 2023, Medical Journals/Acta D-V. All rights reserved.
PY - 2023
Y1 - 2023
N2 - The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score. A systematic review fol-lowing Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane libra-ry. All studies investigating the efficacy of treatments for alopecia areata were included. Primary outcomes were the proportion of patients with alopecia areata achieving 30%, 50%, 75%, 90% and 100% improvement in SALT score after treatment with a Janus kinase inhibitor. A meta-analysis was performed including all randomized controlled trials investigating Janus kinase inhibitors. A total of 37 studies matched the inclusion criteria and were included. Meta-analysis was performed based on 5 randomized studies. Regarding patients with alopecia areata defined as ≥ 50% scalp hair loss, baricitinib 4 mg once daily demonstrated the highest efficacy. However, among patients with alope-cia areata defined as a SALT score ≥ 50, oral deurux-olitinib 12 mg twice daily demonstrated the highest efficacy. Deuruxolitinib and baricitinib appear to be promising drugs for the treatment of alopecia areata. However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are requi-red to confirm these findings.
AB - The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score. A systematic review fol-lowing Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed using Medline, EMBASE and Cochrane libra-ry. All studies investigating the efficacy of treatments for alopecia areata were included. Primary outcomes were the proportion of patients with alopecia areata achieving 30%, 50%, 75%, 90% and 100% improvement in SALT score after treatment with a Janus kinase inhibitor. A meta-analysis was performed including all randomized controlled trials investigating Janus kinase inhibitors. A total of 37 studies matched the inclusion criteria and were included. Meta-analysis was performed based on 5 randomized studies. Regarding patients with alopecia areata defined as ≥ 50% scalp hair loss, baricitinib 4 mg once daily demonstrated the highest efficacy. However, among patients with alope-cia areata defined as a SALT score ≥ 50, oral deurux-olitinib 12 mg twice daily demonstrated the highest efficacy. Deuruxolitinib and baricitinib appear to be promising drugs for the treatment of alopecia areata. However, the response depends on the dosage of the drug. More randomized trials, with identical inclusion criteria and dose and duration of treatment, are requi-red to confirm these findings.
KW - alopecia areata
KW - biological
KW - JAK inhibitors
KW - polygenic autoimmune disease
U2 - 10.2340/actadv.v103.4536
DO - 10.2340/actadv.v103.4536
M3 - Review
C2 - 36695751
AN - SCOPUS:85146875009
VL - 103
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
M1 - adv00855
ER -
ID: 363062810